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Abstract
Heart transplantation can drastically improve survival in patients with a failing
heart; however, the shortage of donor hearts remains a serious problem with this
treatment strategy and the successful clinical application of regenerative medi-
cine is eagerly awaited. To this end, we developed a novel method to generate
human induced pluripotent stem cells (iPSCs) from circulating human T
lymphocytes using Sendai virus containing Yamanaka factors. To establish an
efficient cardiac differentiation protocol, we then screened factors expressed in
the future heart site of early mouse embryos and identified several growth factors
and cytokines that can induce cardiomyocyte differentiation and proliferation.
Subsequent transcriptome and metabolome analysis on undifferentiated stem
cells and cardiomyocytes to devise a specific metabolic environment for
cardiomyocyte selection revealed completely different mechanisms of glucose
and lactate metabolism. Based on these findings, we succeeded in metabolically
selecting cardiomyocytes using glucose-free and lactate-supplemented medium,
with up to 99 % purity and no teratoma formation. Using our aggregation
technique, we also showed that >90 % of the transplanted cardiomyocytes
survived in the heart and showed physiological growth after transplantation.
We expect that combining these techniques will achieve future heart
regeneration.
Keywords
Induced pluripotent stem cell • Purification • Cardiomyocyte • Transplantation •
Human
S. Tohyama • K. Fukuda (*)
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
e-mail: kfukuda@a2.keio.jp
# The Author(s) 2016




Heart disease remains a leading cause of death despite recent medical advances, and
heart transplantation remains the ultimate treatment for severe heart failure. How-
ever, limited donor numbers remain an unsolved problem for transplantation
therapy, and both patients and clinicians hold great hope for the future success of
heart regenerative cell therapies as an alternative strategy [1]. Pluripotent stem cells
(PSCs) including embryonic stem cells (ESCs) and induced pluripotent stem cells
(iPSCs) can self-renew infinitely and are potential mass production sources for
therapeutic cardiomyocytes. In particular, human iPSCs have the huge advantage of
avoiding immunological rejection after cell transplantation.
Human iPSCs were first generated from dermal fibroblasts by Takanashi and
Yamanaka in 2007 [2], using a retroviral transduction system. Subsequently, the
methodology for generating iPSCs has dramatically improved. We previously
reported that integration-free iPSCs could be easily and rapidly generated from
terminally differentiated circulating T lymphocytes in peripheral blood using
Sendai virus [3]. Our method makes it possible to generate iPSCs from any patients
including children, girls, and the very elderly by blood sampling alone.
Such cumulative advances in iPSC generation techniques should accelerate the
development of applications for iPSCs generated from patients. However, many
hurdles remain in realizing such applications in human heart regeneration, due
largely to the assumption that one patient will require at least 1 109
cardiomyocytes to recover cardiac function (Fig. 4.1). The important steps to
overcome are as follows: (1) cardiac differentiation efficiencies should be stably
improved regardless of the source cell lines; (2) large-scale cultivation systems will
be required to obtain the billions of differentiated cells required; (3) approximately
1 109 cardiomyocytes should be efficiently collected and residual undifferenti-
ated stem cells should be eliminated from large-scale, mixed, differentiated cell
populations; (4) purified cardiomyocytes should be functionally and electrophysio-
logically characterized; (5) tissue engineering technologies might need to be used
prior to transplantation because dispersed transplanted cardiomyocytes have not yet
achieved high survival rates [4]; and (6) confirmation of safety and efficiency with
these techniques is essential in large animal models before clinical application. In
this chapter, we discuss these hurdles to realizing heart regenerative therapy in
more detail.
4.2 Cardiac Differentiation from Human iPSCs
Many approaches using ESCs have been investigated to induce cardiac differentia-
tion. In general, the differentiation of ESCs into any cell lineage is based on the
mechanism of normal early development [5]. The visceral endoderm is known to
play a key role in the differentiation of cardiac precursors that are present in the
adjacent mesoderm during development, and Mummery et al. [6] previously
reported that human ESCs effectively differentiate into cardiomyocytes when
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cocultured with mouse visceral endoderm-like (END-2) cells. In an attempt to
improve cardiac differentiation efficiencies inexpensively and easily, Takahashi
et al. [6] screened a chemical compound library approved by the United States Food
and Drug Administration (FDA) and found that ascorbic acid efficiently induced
cardiac differentiation. However, this chemical alone might be not enough to
induce cardiac differentiation from iPSCs.
Several studies have shown that various combinations of heart development-
related proteins including BMP, activin, Wnt, BMP inhibitor, and Wnt inhibitor
induce cardiomyocytes from ESCs [7–10]. We reported that the context-dependent
differential action of BMPs in cardiomyocyte induction is explained by the local
action of Noggin and other BMP inhibitors and, accordingly, developed a protocol
to induce cardiac differentiation of mouse ESCs through transient administration of
Noggin [9]. However, to obtain hundreds of millions of cardiomyocytes, it is
necessary to establish a cardiac differentiation method that is both efficient and
cost-effective due to the many expensive recombinant protein factors used. To
address this problem, Minami et al. [11] screened small-molecule compounds to
identify those that significantly increase cardiac differentiation induction, and they
revealed some inhibitors of canonical Wnt signaling as candidates. In addition,
Fig. 4.1 Overview of steps to overcome for realization of heart regenerative therapy. The critical
hurdles to overcome are as follows: (1) improvement of cardiac differentiation efficiencies,
(2) establishment of large-scale cultivation systems, (3) purification of large-scale
cardiomyocytes, (4) electrophysiological characterization, (5) utilization of appropriate tissue
engineering technologies, and (6) confirmation of safety and efficiency in large animal models
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recently novel efficient protocols using small molecules and/or chemically defined
media have been reported (Lian et al. Nat Protocols 2013;8:162–175, Burridge
et al. Nat Methods. 2014;11:855–60).
Several studies then showed that induction techniques in ESCs could also be
applied to iPSCs, although differentiation efficiencies were suggested to be inferior
compared to ESCs. However, as such differentiation efficiencies vary greatly with
different cell lines [12], further investigation is needed in the future. Furthermore,
to efficiently obtain large quantities of cardiomyocytes inexpensively, it is neces-
sary to continue refining efficient cardiac differentiation systems combined with the
use of small-molecule compounds. However, despite improved cardiac differentia-
tion efficiencies, it is inevitable that human PSC derivatives will contain not only
cardiomyocytes but also undifferentiated stem cells and/or noncardiac cells because
all PSCs cannot differentiate into cardiomyocytes. Therefore, to confirm safety
after transplantation, it is necessary to remove noncardiac cells and undifferentiated
stem cells that could cause tumors.
4.3 Nongenetic Methods for Purifying Cardiomyocytes
One of the biggest risks with in vitro-generated cardiomyocytes for clinical use is
teratoma formation due to residual PSC contamination [13]. Current procedures for
eliminating such contamination and boosting cardiomyocyte enrichment involve
genetic modification [14, 15] and nongenetic methods using a mitochondrial dye
[16] or antibodies to specific cell-surface markers [17]. However, none of these
methods are ideal for the therapeutic application of PSC-derived cardiomyocytes
due to insufficient stability, genotoxicity, and the use of fluorescence-activated cell
sorting (FACS). To address this issue, we sought to purify cardiomyocytes effi-
ciently and inexpensively, based on differences among cell-specific nutrition
sources.
To create a metabolic environment where “residual undifferentiated stem cells
cannot survive and only cardiomyocytes can survive,” we performed metabolome
and transcriptome analysis in neonatal cardiomyocytes and PSCs. We found that
these PSCs mainly depended on activated glycolysis and actively discharged lactate
into the extracellular media. In addition, biomass needed for proliferation such as
amino acids and nucleic acids were actively synthesized in PSCs compared to
cardiomyocytes. On the other hand, cardiomyocytes mainly depended on oxidative
phosphorylation in mitochondria to obtain adenosine triphosphate (ATP) effi-
ciently. We also performed metabolome analysis to demonstrate that other noncar-
diac proliferating cells also depended on glycolysis, like PSCs. Thus,
cardiomyocytes and proliferating noncardiac cells including PSCs showed
differences in metabolism (Fig. 4.2) that we then successfully exploited to select
cardiomyocytes from human PSCs efficiently and inexpensively simply by chang-
ing the cell-specific medium to one that is glucose depleted and lactate
supplemented [18]. The cardiomyocytes selected by metabolism showed normal
electrophysiological properties and did not form teratoma after transplantation.
28 S. Tohyama and K. Fukuda
Furthermore, we succeeded to establish a practical culture system for generating
substantial numbers of purified cardiomyocytes by combining a massive suspension
culture system with a metabolic selection medium (Hemmi et al. Stem Cells Transl
Med. 2014;3:1473–83).
4.4 Transplantation of Human PSC-Derived Cardiomyocytes
Many studies have been conducted regarding cell transplantation therapies in
animal models using human PSC-derived cardiomyocytes. The survival of dis-
persed transplanted cardiomyocytes is reportedly very low [4], and some ingenuity
is required in the method of transplantation. Our group previously reported that
transplanted cell survival was dramatically improved by transplantation after for-
mation of cardiomyocyte aggregates [16], while Laflamme et al. [9] showed a
similar effect using a prosurvival cocktail that inhibited apoptosis.
With regard to the effectiveness of cell transplantation, Laflamme et al. [9]
also demonstrated that transplanted human ESC-derived cardiomyocytes could
improve cardiac function after 4 weeks in a rat myocardial infarction model. In
addition, Shiba et al. [20] demonstrated that transplanted human ESC-derived
cardiomyocytes electrically coupled to the host cardiomyocytes and suppressed
arrhythmias in a guinea pig myocardial infarction model. Furthermore, with respect
to cell transplantation in large animals, Kawamura et al. [19] recently reported that
cardiac cell sheets comprising purified human iPSC-derived cardiomyocytes
generated using our method [18] improved cardiac function in a pig myocardial
infarction model. Thus, efficacies have been achieved in cell transplantation
Fig. 4.2 Distinct metabolic differences between cardiomyocytes and other proliferating cells
including undifferentiated stem cells. Cardiomyocytes efficiently obtain ATP mainly via oxidative
phosphorylation, while other proliferating cells including PSCs obtain ATP, nucleotide, and amino
acids via activated glycolysis
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therapies using human iPSC-derived cardiomyocytes, although many such studies
showed only short-term effectiveness. Thus, careful evaluation of the efficacy and
safety of human iPSC-derived cardiomyocytes in cell transplantation over the
longer term must be ongoing.
4.5 Future Directions
The discovery and refinement of human iPSCs generation is expected to advance
not only regenerative medicine but also drug discovery and analyses of genetic
disorders using patient-specific iPSCs [19]. The major and common problem
remaining in this quest is securing sufficient numbers of mature and functional
cardiomyocytes with high purity. To solve this problem, it is essential to develop a
stable and efficient mass culture system and to establish a simple system to analyze
the electrophysiological function of the generated cardiomyocytes (Fig. 4.1). Fur-
thermore, the future realization of clinical applications using human iPSCs will
necessitate a better understanding of the cell biology and techniques involved in
tissue engineering generally. Only then will we be able to achieve long-term safety
and efficacy in the heart failure models of large animals and finally realize human
heart regenerative therapies.
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